CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore patent oppositions filed by Intas Pharmaceuticals against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Jul 31, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Methods For Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Protein ReductionNOVARTISJan 16, 2025
Fixed Dose Combinations Comprising Etc1002 And One Or More Statins For Treating Or Reducing Cardiovascular RiskESPERION THERAPEUTICSAug 1, 2024
Methods Of Administering Fluvoxamine TherapyINTERMUNEFeb 19, 2021
Methods Of Administering Pirfenidone TherapyINTERMUNEFeb 15, 2021
Apixaban FormulationsBRISTOL MYERS SQUIBB IRELANDAug 12, 2020
Apixaban FormulationsBRISTOL MYERS SQUIBB IRELANDJul 15, 2020
Apixaban FormulationsBRISTOL MYERS SQUIBB IRELANDJul 15, 2020
Apixaban FormulationsBRISTOL MYERS SQUIBBSep 4, 2019
Direct Compression Formulation And ProcessNOVARTISFeb 15, 2019
Pharmaceutical Compositions Containing Dexketoprofen And TramadolLABORATORIOS MENARINIJan 18, 2019

Explore Intas Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 31, 2025
Patent NumberGrant DateTitleTotal Oppositions
Aug 31, 2022Pharmaceutical Composition Comprising Hmg-Coa Reductase Inhibitors And Fenofibrate2
Nov 13, 2019Stable Tigecycline Composition1
Mar 20, 2019Process For The Preparation Of Cabazitaxel And Its Intermediates1

Top competitors of Intas Pharmaceuticals

List of top competitors of Intas Pharmaceuticals based on patent oppositions.